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Abstract
Bergazym® P is a preparation of endo-1,4-b-xylanase (xylanase) that is intended to be used as a
zootechnical additive in feed for chickens for fattening, weaned piglets and pigs for fattening at a dose
of 1,500 EPU/kg feed. The xylanase is produced by a non-genetically modiﬁed strain of Trichoderma
reesei. The EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)
concluded from the tolerance studies submitted that the additive is safe for chickens for fattening and
weaned piglets at 1,500 EPU/kg feed. The conclusions were extended to pigs for fattening. The results
obtained with the enzyme concentrate used to formulate the additive in the genotoxicity studies and in
the sub-chronic oral toxicity study do not indicate any reason for concern for consumer safety arising
from the use of the product as feed additive. From the data provided on the enzyme concentrate used
to formulate the additive, the Panel concluded that the additive is not irritant to skin or eyes but it is
considered a potential skin sensitiser. Owing to the proteinaceous nature of the active substance, the
additive is considered a potential respiratory sensitiser. The FEEDAP Panel concluded that no risks to
the environment are expected. To support the efﬁcacy of the additive, the applicant submitted ﬁve
trials in chickens for fattening, ﬁve in weaned piglets and three in pigs for fattening. The FEEDAP
Panel could not conclude on the efﬁcacy of the additive in chickens for fattening and weaned piglets,
but concluded that the additive has the potential to be efﬁcacious in pigs for fattening at the
recommended dose.
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of European Food Safety Authority.
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Summary
Following a request from the European Commission, the Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on the safety and
efﬁcacy of Bergazym® P100 (endo-1,4-b-xylanase) as a feed additive for chickens for fattening,
weaned piglets and pigs for fattening.
Bergazym® P100 is a feed additive with endo-1,4-b-xylanase (xylanase) as the main enzyme
activity which is available in solid form. The xylanase is produced by a non-genetically modiﬁed strain
of Trichoderma reesei.
The results found in the tolerance trials provided in chickens for fattening and weaned piglets
showed that the animals can tolerate 200- or 100-fold the recommended dose of 1,500 EPU/kg feed,
respectively. Therefore, the FEEDAP Panel concluded that the additive is safe for these target species/
categories. The conclusions reached for the weaned piglets were extended to pigs for fattening.
The enzyme concentrate used to formulate the additive was tested in genotoxicity studies and in a
sub-chronic oral toxicity study. The results of these tests did not indicate any reason for concern for
consumer safety arising from the use of the product as feed additive. Therefore, the Panel concluded
that the additive is safe for the consumers.
The enzyme concentrate did not prove irritant for skin or eye but proved positive in the skin
sensitising test. The Panel considered that the ingredients used to formulate the additive are not likely
to contribute to the irritant properties and therefore concluded that the additive is not irritant to skin
and eyes but is considered a potential skin and respiratory sensitiser.
The FEEDAP Panel concluded that the use of Bergazym® P100 as a feed additive poses no risks to
the environment.
To support the efﬁcacy of the additive, the applicant submitted ﬁve trials in chickens for fattening,
ﬁve in weaned piglets and three in pigs for fattening. From these studies the Panel identiﬁed the need
for further studies in order to conclude on the efﬁcacy of the additive in chickens for fattening and
weaned piglets. The Panel concluded that the additive has the potential to be efﬁcacious in pigs for
fattening at the recommended dose.
Bergazym® P100 for chickens and pigs
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an
application in accordance with Article 7.
The European Commission received a request from Berg + Schmidt GmbH Co. KG2 for authorisation
of the product Bergazym® P100 (endo-1,4-b-xylanase), when used as a feed additive for chickens for
fattening, weaned piglets and pigs for fattening (category: zootechnical additives; functional group:
digestibility enhancers).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the
application to the European Food Safety Authority (EFSA) as an application under Article 4(1)
(authorisation of a feed additive or new use of a feed additive). The particulars and documents in
support of the application were considered valid by EFSA as of 24 June 2015.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether
the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on
the safety for the target animals, consumer, user and the environment and on the efﬁcacy of the
product Bergazym® P100 (endo-1,4-b-xylanase), when used under the proposed conditions of use
(see Section 3.1.5).
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier3 in support of the authorisation request for the use of Bergazym® P100 as a feed additive. The
technical dossier was prepared following the provisions of Article 7 of Regulation (EC) No 1831/2003,
Regulation (EC) No 429/20084 and the applicable EFSA guidance documents.
EFSA has veriﬁed the European Union Reference Laboratory (EURL) report as it relates to the
methods used for the control of the active substance in animal feed. The Executive Summary of the
EURL report can be found in Annex A.5
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of Bergazym®
P100 is in line with the principles laid down in Regulation (EC) No 429/20084 and the relevant guidance
documents: Guidance on zootechnical additives (EFSA FEEDAP Panel, 2012a), Technical guidance:
Tolerance and efﬁcacy studies in target animals (EFSA FEEDAP Panel, 2011), Guidance for establishing
the safety of additives for the consumer (EFSA FEEDAP Panel, 2012b), Guidance on studies concerning
the safety of use of the additive for users/workers (EFSA FEEDAP Panel, 2012c), Technical Guidance:
Microbial Studies (EFSA, 2008a), Technical Guidance: Extrapolation of data from major species to minor
species regarding the assessment of additives for use in animal nutrition (EFSA, 2008b, revised in 2009)
and Technical Guidance for assessing the safety of feed additives for the environment (EFSA, 2008c).
3. Assessment
Bergazym® P100 (endo-1,4-b-xylanase; xylanase (Enzyme Commission number: 3.2.1.8)) is intended
to be used as a zootechnical additive, functional group of digestibility enhancers, for chickens for
fattening, weaned piglets and pigs for fattening.
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 Berg + Schmidt GmbH Co. KG, An der Alster 81, 20099 Hamburg, Denmark.
3 FEED dossier reference: FAD-2014-0029.
4 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
5 The full report is available on the EURL website https://ec.europa.eu/jrc/sites/default/files/FinRep-FAD-2014-0029.pdf
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3.1. Characterisation
3.1.1. Characterisation of the active substance
Bergazym® P100 contains a xylanase produced by a non-genetically modiﬁed strain of Trichoderma
reesei deposited at the Belgian Coordinated Collections of Microorganisms with the accession number
BCCM/MUCL 49755 (for an undeﬁned period, dated 2011).6 The additive also contains cellulase and
b-glucanase as side activities.7
3.1.2. Manufacturing process8
The enzyme is produced in a multistep process including fermentation, ﬁltration and concentration.
The resulting product is formulated with wheat meal and starch. The applicant stated that no
antimicrobial substances are used in the manufacture of the product.
3.1.3. Characterisation of the additive
The additive is available in a coated granular form which contains 2.6% of enzyme concentrate,
wheat meal (96.7%) and starch (0.7%).9 The additive is speciﬁed to a minimum activity of
15,000 EPU10 /g. The study of the batch to batch variation in six batches showed a mean enzyme
activity of 15,317 EPU/g with a coefﬁcient of variation (CV) of 3.3%.11
Three to four batches of the additive were analysed for microbiological contamination and chemical
contamination.12 The analyses of chemical contamination included arsenic (< 0.5 mg/kg), cadmium
(< 0.5 mg/kg), lead (< 1.5 mg/kg), mercury (< 0.02 mg/kg), ﬂuorine (< 5 mg/kg, only one batch),
polychlorinated dibenzo-p-dioxins (PCDD) and polychlorinated dibenzofurans (PCDF) (WHO-PCDD/
F-TEQ ≤ 0.184 ng/kg), dioxin-like PCBs (WHO-PCB-TEQ ≤ 0.067 lg/kg) and sum of PCDD and PCDF
and dioxin-like PCBs (WHO-PCDD/F-PCB-TEQ ≤ 0.250 ng/kg). Microbiological analysis included
Salmonella spp. (absent in 25 g), Escherichia coli (< 10 colony forming units (CFU)/g), coliforms
(≤ 30 CFU/g), total viable aerobic counts (≤ 103 CFU/g, two batches), yeasts and moulds (≤ 102 CFU/
g, two batches). The absence of the production strain was demonstrated in one further batch.13 The
following mycotoxins were also analysed: aﬂatoxin B1, B2, G1 and G2 (< 1.7 lg/kg), zearalenone
(< 17 lg/kg), deoxynivalenol (< 40 lg/kg),14 ochratoxin A (< 21 lg/kg, two batches), fumonisin
(< 47 lg/kg, two batches) and citrinin (< 111 lg/kg, two batches). The presence of other secondary
metabolites was investigated14; trichodermins (below limit of detection (LOD) 4 lg/kg), trichodimerols
(below LOD 2 lg/kg), sorbicillactones (below LOD 800 lg/kg). One batch of the product was
investigated for the presence of antimicrobial activity. The results showed absence of antimicrobial
activity (according to EFSA, 2008a).15
Particle size was studied in three batches by laser diffraction and showed that particles below
100 lm amount ~ 2.4%, below 52 lm amount ~ 1.3% and below 18 lm amount 0.5% (v/v).16
Dusting potential of three batches, measured following the Stauber–Heubach method, ranged from 0
to 0.02 g/m3).17
3.1.4. Stability and homogeneity
The shelf-life of the additive was investigated in three batches. Samples were stored in closed
plastic bags for 6 months at three different temperatures, 25, 30 or 40°C.17 After 6 months, the mean
enzyme recoveries of the initial enzyme activity were 90% at 25°C, 84% at 30°C and 60% at
6 Technical dossier/Supplementary information November 2016/Annexes 1.1, 1.4 and 2. Deposition for an undeﬁned period,
letter dated 2011.
7 Technical dossier/Supplementary information November 2016/Annexes 7.1 to 7.3.
8 This section has been amended following the conﬁdentiality claims made by the applicant.
9 Technical dossier/Supplementary information November 2016.
10 Technical dossier/Section II/Annex 2.6.1./One EPU, endopentosanase unit, is deﬁned as the amount of enzyme required to
release 0.0083 µmol of reducing sugar equivalents (xylose equivalents) from oat spelt xylan per minute at pH 4.7 and 50°C.
11 Technical dossier/Section II/Annexes 2.1.3.a and 2.1.3.b.
12 Technical dossier/Section II/Annexes 2.1.4.a and 2.1.4.b and Supplementary information November 2016/Annex 9.
13 Technical dossier/Supplementary information November 2016/Annex 11.
14 Technical dossier/Supplementary information November 2016/Annex 4.
15 Technical dossier/Supplementary information November 2016/Annex 10.
16 Technical dossier/Section II/Annex 2.1.5.
17 Technical dossier/Section II/Annex 2.1.3.b.
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40°C.Three batches of the additive were incorporated to a vitamin–mineral premixture for poultry feed
(without choline chloride) at a dose of 200 EPU/g.17 Samples were kept in closed plastic bags for 3
and 6 months at 25°C. Mean recoveries of the initial enzyme activity after 3 and 6 months of storage
were 75% and 79%, respectively.
The stability to pelleting was measured by incorporating three batches of the additive to a complete
feed for poultry species at a dose of 2,400 EPU/kg.17 The mash feed was pelleted and the enzyme
activities were measured in samples taken after conditioning at 75°C and after pelleting (temperature
in the outlet 81°C). The mean recoveries of the initial enzyme activity at these two points were 84%
and 49%, respectively, indicating low stability at those temperatures. In a further test at 68°C,18 the
recovery was 95%.
The stability in mash feed and pelleted feed was studied in complete feed for chickens for fattening
in mash (two different studies) or pelleted form supplemented at 2,000 EPU/kg feed.19 Samples were
stored at 25°C for 3 months. In a ﬁrst study in mash feed, mean recovery of the initial enzyme activity
after 3 months was 62% and in the second study no loss of activity was found. In pelleted feed, no
loss of activity was found after 3 months.
The capacity of the additive to homogeneously distribute in feed was studied in 10 sub-samples of
four batches of mash feed and in two batches of pelleted feed.20 In the mash feed the CV values
ranged from 12% to 56%, indicating low capacity to distribute homogeneously. I n the pelleted feed
the values were below 10%.
3.1.5. Conditions of use
Bergazym® P100 is intended to be used as a feed additive for chickens for fattening, weaned
piglets and pigs for fattening at a recommended dose of 1,500 EPU/kg feed.
3.2. Safety
3.2.1. Safety for the target species
3.2.1.1. Safety for chickens for fattening
Two tolerance trials were provided. One of them21 was not considered further in the assessment
because the animals were not healthy; the birds suffered from an episode of necrotic enteritis for
which they had to be medically treated (4 days of antibiotic) and which resulted in a high mortality/
culling in all treatments (mean 14.5%).
In the second study,22 a total of 144 one-day-old female Ross 308 chickens were distributed to 24
wire-ﬂoor cages in groups of six chickens each and allocated to three dietary treatments (representing
eight replicate cages per treatment). Basal diets (starter and grower) based on wheat, rye and
soybean were either not supplemented (control) or supplemented with Bergazym® P100 to provide
1,500 (19) or 300,000 EPU/kg feed (2009). The enzyme activity was conﬁrmed by analysis. Feed and
water were available ad libitum over an experimental period of 35 days. General health status and
mortality were monitored daily. Body weight and feed intake were recorded at days 1, 14 and 35, and
feed to gain ratio calculated. An analysis of variance (ANOVA) was performed with the data
considering the cage was the experimental unit. Group means were compared with the least signiﬁcant
difference test. Signiﬁcance level was set at p < 0.05.
Five birds died during the study, two in the control, two in the 19 and one in the 2009. Daily feed
intake of the birds was 97.8, 96.6 and 93.6 g/day in the control, 19 and 2009, respectively. The
corresponding ﬁgures for body weight were 2,053, 2,106 and 2,147 g and for feed to gain ratio were
1.70, 1.64 and 1.56. The 200-fold supplementation did not adversely affect the health and
performance of the birds. Therefore, the FEEDAP Panel concludes that the additive is safe for chickens
for fattening at the recommended dose.
18 Technical dossier/Section II/Annex 2.4.1.a.
19 Technical dossier/Section II/Annex 2.1.3.b, Annex 2.4.1.a and Annex 2.4.1.b.
20 Technical dossier/Section II/Annex 2.1.3.b, Annex 2.4.2. and Supplementary information November 2016/Annex 16.
21 Technical dossier/Section III/Annex 3.1.1.e 14-21 Final report, Annex 3.1.1.f, Annex 3.1.1.g, and Annex 3.1.1.h.
22 Technical dossier/Supplementary information November 2016/Annex 18.1.a–d.
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3.2.1.2. Safety for weaned piglets
Two tolerance trials were provided. One of them23 was not considered further due to the extensive
treatment with antibiotics administered to the piglets (6–8 days via feed).
In the second tolerance trial,24 a total of 135 weaned male and female piglets (Landrace 9 Large
White, initial body weight 5.01 kg) were distributed to pens in groups of ﬁve piglets each (mixed
gender) and allocated to three dietary treatments (representing nine replicate pens per treatment).
Basal diets (pre-starter and starter) based on wheat, barley, rye and soybean were either not
supplemented (control) or supplemented with Bergazym® P100 to provide 1,500 (19) or 150,000
(1009) EPU/kg feed. The enzyme activity in the feed was conﬁrmed by analysis. Feed and water were
available ad libitum over an experimental period of 42 days. General health status and mortality were
monitored daily. Body weight and feed intake were recorded at days 1, 14 and 42, and average daily
gain, average daily feed intake and feed to gain ratio calculated. An ANOVA was performed with the
data considering the pen as the experimental unit. Signiﬁcance level was set at p < 0.05.
Five animals died during the study (mean mortality value of 4.5%); four piglets died in the 19 dose
(two due to digestive disorders, one with meningitis and another one with septicaemia) and one piglet
died in the 1009 (at the pre-starter phase with signs of anorexia). Three more piglets were removed
from the study, two from 19 (low performer, meningitis) and one from 1009 (low performer). No
animals died or were culled in the control, the mortality/culling registered in the 19 dose was 13%
and in the 1009 was 5.7%. The daily feed intake was 425, 423 and 422 g/day for control, 19 and
1009, respectively. The corresponding ﬁgures for ﬁnal body weight were 17.4, 17.5 and 17.6 kg and
the feed to gain ratio was 1.44, 1.42 and 1.41. There were no signiﬁcant effects of the addition of
Bergazym® P100 on the performance parameters considered.
The group receiving the recommended dose showed a high mortality/culling rate. Considering the
likely cause of death reported, that no other negative effects on the performance of the piglets in the
recommended dose group were identiﬁed and that this high mortality rate was not found in the piglets
receiving 1009, the FEEDAP Panel considers that this mortality is not related to the dietary treatment.
Therefore, the FEEDAP Panel concludes that the additive is safe for the weaned piglets at the
recommended dose.
3.2.1.3. Safety for pigs for fattening
No speciﬁc study was provided to demonstrate the tolerance of pigs for fattening. The FEEDAP
Panel considers that the conclusions reached with regard to weaned piglets can be extended to pigs
for fattening.
3.2.1.4. Conclusions on the safety for the target species
The results from the tolerance trials provided in chickens for fattening and weaned piglets showed
that the animals can tolerate 200 or 100-fold the recommended dose of 1,500 EPU/kg feed,
respectively. Therefore, the FEEDAP Panel concludes that the additive is safe for these target species
at the recommended dose. The conclusions reached for the weaned piglets can be extended to pigs
for fattening.
3.2.2. Safety for the consumer
In the studies presented below, the test item was the enzyme concentrate used to formulate the
additive.9
3.2.2.1. Genotoxicity studies
Bacterial reverse mutation assay
The test substance diluted in dimethylsulphoxide was examined for mutagenic activity in the
bacterial reverse mutation test using the Salmonella Typhimurium strains TA 1535, TA 1537, TA 98, TA
100 and the Escherichia coli strain WP2 uvrA, in the absence and presence of a liver fraction of Aroclor
1254-induced rats for metabolic activation (S9-mix) according to OECD Guideline 471.25 The maximum
concentration was 5,000 lg/plate. The test item did not induce any dose-related or more than twofold
23 Technical dossier/Section III/Annex 3.1.1.a–d.
24 Technical dossier/Supplementary information November 2016/Annex 16.a–b.
25 Technical dossier/Section III/Annex 3.2.2.a.
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increase in the number of revertant colonies, whereas the positive controls gave the expected
mutagenic effect.
In vitro chromosomal aberration test
The test substance, diluted in dimethylsulphoxide, was examined for its potential to induce
structural chromosomal aberrations in Chinese hamster ovary cells, in both the absence and presence
of a metabolic activation system (S9-mix) in compliance with OECD Guideline 473 (rev.1997).26 Two
separate tests were conducted. In the ﬁrst test, the treatment/harvesting times were 4/18 h (pulse
treatment) both in the absence and in the presence of S9-mix. In the second test, a pulse treatment
was applied in the presence of S9-mix and a continuous treatment of 18 h, directly followed by
harvesting, in the absence of S9-mix. In all instances, duplicate cultures were used.
The highest concentration tested was based on the solubility of the test substance in the culture
medium. In the pulse treatment, slight cytotoxicity was reported at the two highest concentrations of
1,500 and 1,000 lg/mL; in the continuous treatment, clear cytotoxicity was reported at the two
highest concentrations of 600 and 400 lg/mL. The test substance did not induce any statistically
signiﬁcant increase in the number of aberrant cells in any experimental condition, whereas the positive
control performed as expected.
3.2.2.2. Sub-chronic oral toxicity study
The study was conducted in accordance with OECD guideline 408.27 The trial was carried out over
13 weeks in groups of 10 Wistar rats of each sex, caged in groups of ﬁve. There was a total of seven
experimental groups, with one negative control, three groups given diets containing the test item at
500, 1,500 and 4,000 mg/kg body weight and day. The other three groups are not relevant to the
current assessment. The enzyme activity of the experimental diets was conﬁrmed by analysis. There
were no signiﬁcant adverse effects of treatment on any of the parameters observed during or at the
end of the experimental period.
3.2.2.3. Conclusions on the safety for the consumer
The results obtained with the enzyme concentrate used to formulate the additive in the
genotoxicity studies and in the sub-chronic oral toxicity study do not indicate any reason for concern
for consumer safety arising from the use of the product as feed additive.
3.2.3. Safety for the user
In the studies presented below, the test item was the enzyme concentrate used to formulate the
additive.9
3.2.3.1. Respiratory system
No speciﬁc studies were provided to address the effects of the additive on the respiratory system.
Owing to the proteinaceous nature of the active substance, the additive is considered as a potential
respiratory sensitiser. However, the inhalation exposure is expected to be low because the dusting
potential of the product is negligible.
3.2.3.2. Skin and eyes
The irritant properties of the fermentation product to skin and eyes were evaluated in rabbits
according to OECD test Guidelines 404 and 405, respectively.28 The test item was classiﬁed as not
irritant.
The skin sensitising potential of the fermentation product was evaluated in the local lymph node
assay in mouse following OECD test Guideline 429.29 No signs of irritancy were found. From the results
obtained, the test item should be regarded as a skin sensitiser.
3.2.3.3. Conclusions on safety for the user
The enzyme concentrate is not irritant to skin or eye but is a skin sensitiser. The ingredients used
to formulate the additive are not likely to contribute to the irritant properties and therefore the
26 Technical dossier/Section III/Annex 3.2.2.b.
27 Technical dossier/Section III/Annexes 3.2.2.3a–c.
28 Technical dossier/Section III/Annexes 3.3.1.2.b and 3.3.1.2.c.
29 Technical dossier/Section III/Annex 3.3.1.2.a.
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additive is not irritant to skin and eyes. The additive is considered a potential skin and respiratory
sensitiser.
3.2.4. Safety for the environment
The active substance of the additive is a protein, and as such will be degraded/inactivated during
passage through the digestive tract of animals or in the environment. Therefore, no risks to the
environment are expected and no further environmental risk assessment is required.
3.3. Efﬁcacy
3.3.1. Efﬁcacy in chickens for fattening
Five long-term trials in chickens for fattening were submitted. Two of these studies were not
considered further. One30 was not considered further due to the unavailability of relevant data/
information including methodologies followed, analytical data of the feed offered and data regarding
the animals. The other study was the ﬁrst tolerance study described above (see Section 3.2.1.1)31
which could not be considered because the birds were not healthy.
Details of the design of the three studies considered are provided in Table 1 and the results in
Table 2. The third study is the second tolerance study presented in Section 3.2.1.1. In all trials, 1-day-
old birds were used and at least two experimental groups were considered, a control group and a
group receiving the recommended dose. Enzyme dosage was not conﬁrmed in study 1. The health of
the animals and mortality were monitored throughout the study and the body weight and feed intake
were recorded. Feed to gain ratio was calculated. In the ﬁrst trial there were measurements on the
utilization of the diets, however, these data did not include the measurement of the energy and
therefore it is not presented below. An ANOVA was performed with the data obtained considering the
pen as the experimental unit. The comparison of the mean groups was performed with the Tukey test
in trial 1 and with the least signiﬁcant difference test in trials 2 and 3. Signiﬁcance level was set at
p < 0.05.
A higher body weight (trial 1) and/or a better feed to gain ratio (trials 1 and 3) were found in the
birds receiving the recommended dose compared to the control in two trials. However, both trials
showed limitations. In trial 1, the enzyme activity in feed was not conﬁrmed. In trial 3, although the
differences were reported as signiﬁcant the statistical test to compare group means used does not
correct for multiple comparisons (three groups). An adequate statistical analysis was not provided.
Table 1: Trial design and dosages of the efﬁcacy trials performed in chickens for fattening
Trial
Total no. animals
(animals/replicate)
Replicates/treatment
Breed
Duration
Sex
Diet composition of
the diets
Enzyme activity
(EPU/kg feed)
Intended Analysed
1(a) 600
(50)
4
Cobb 500
49
♂/♀
Maize, soya bean meal 0
1,500
3,000
Not provided
2(b) 96
(6)
8
Ross 308
35
♀
Wheat, rye, barley, soya
bean meal
0
1,500
390
1,285
3(C) 144
(6)
8
Ross 308
35
♀
Wheat, rye, soya bean
meal
0
1,500
300,000
388
1,365
446,000
(a): Technical dossier/Section IV/Annex 4.3.1.2.a–b. and Supplementary information November 2016/Annex 19.
(b): Technical dossier/Supplementary information November 2016/Annex 18.2.a–d.
(c): Technical dossier/Supplementary information November 2016/Annex 18.1.a–d.
30 Technical dossier/Section IV/Annexes 3.1.1.a–b.
31 Technical dossier/Section III/Annexes 3.1.1.e–h.
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3.3.1.1. Conclusions in chickens for fattening
The FEEDAP Panel considers that there is insufﬁcient evidence to conclude on the efﬁcacy of
Bergazym® P100 in chickens for fattening.
3.3.2. Efﬁcacy in weaned piglets
Two short-term trials and three long-term trials in weaned piglets were submitted to support the
efﬁcacy of the additive.
3.3.2.1. Short-term trials
Two balance trials were considered which followed the same design and methodologies.32,33
Each balance study was performed with eight castrated male weaned piglets (hybrid, approx.
38 days old and initial body weight 16.9 kg in study 1 and 16.3 kg in study 2) housed in individual
digestibility cages and allocated to two dietary treatments (four piglets per treatment). Each balance
study was arranged in a 2 9 4 Latin square design: two phases (rotation) of 7 days each with 4 days
of total collection of faeces and urine (separated) and an adaption period of 7 days. The basal diets,
based on wheat, barley and soya bean meal, were either not supplemented (control) or supplemented
with Bergazym® P100 to provide 1,500 EPU/kg feed. The enzyme activity was conﬁrmed in the two
studies. The diets were fed restrictively at 8% of piglets metabolic weight (body weight0.75).
Body weight of the piglets was recorded at start, days 7, 14 and 21 and feed intake daily during
collection period in both phases. Faeces and urine were totally collected from days 4 to 7 in both
phases. Diets and faeces were analysed for dry matter, crude protein, crude fat and gross energy, and
the apparent faecal digestibilities were calculated. Urine was analysed for nitrogen content and
retention was calculated. The metabolisable energy content of the diets was calculated using the data
on the apparent faecal digestibility and the energy excreted through urine (in the form of nitrogen). An
ANOVA was performed with the data. Signiﬁcance level was set at p < 0.05.
The metabolisable energy content of the diets for the ﬁrst experiment was 15.0 and 15.4 MJ/kg feed
for the control and the recommended dose group, respectively and the values were not signiﬁcantly
different. The corresponding ﬁgures for the second balance study were 14.1 and 14.4 MJ/kg feed,
being the value in the recommended dose group signiﬁcantly higher than in the control. Therefore, in
one balance study, a higher metabolisable energy content of the diet was obtained in piglets fed the
recommended dose.
3.3.2.2. Long-term trials
Three long-term trials were submitted. One of these trials, the ﬁrst tolerance trial23 (see
Section 3.2.1.2), could not be considered further due to the extensive treatment with antibiotics that
was administered to the piglets.
The ﬁrst of the trials considered was the second tolerance trial described in Section 3.2.1.2.24 In
the second study considered,24 a total of 144 weaned male and female piglets (hybrid (Topigs
20 9 Tybor G), approx. 25 days old and initial body weight of 6.5 kg) were distributed to pens in
Table 2: Effects of Bergazym P100 on the performance of chickens for fattening
Trial Treatments
Feed intake
(g)(1)
Final body
weight (g)
Feed to
gain ratio
Mortality and
culling (%)
1 0 5,825 2,857(b) 2.04(a) 4.5
1,500 6,045 3,172(a) 1.91(b) 4.0
3,000 6,020 3,125(a) 1.93(a),(b) 4.0
2 0 93.4 2,021 1.66 2.0
1,500 93.8 2,052 1.63 0
3 0 97.8(a) 2,053(b) 1.70(a) 4.2
1,500 96.6(a),(b) 2,106(a),(b) 1.64(b) 4.2
300,000 93.6(b) 2,147(a) 1.56(c) 2.1
(a),(b): Within a column and within a trial, values with a different superscript are signiﬁcantly different (p < 0.05).
(1): In trial 1, values are total feed intake and in trials 2 and 3, values are daily feed intake.
32 Technical dossier/Section IV/Annex 4.2.2.1.a–i/Supplementary information November 2016/Annex 21.1.a–d.
33 Technical dossier/Section IV/Annex 4.2.2.2.a–i/Supplementary information November 2016/Annex 21.2.a–d.
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groups of six piglets each and allocated to two dietary treatments (representing 12 replicate pens per
treatment). Basal diets (pre-starter and starter) based on wheat, barley, rye and soya bean were
either not supplemented (control) or supplemented with Bergazym® P100 to provide 1,500 EPU/kg
feed. Enzyme activity was conﬁrmed by analysis. General health status and mortality were monitored
daily. Feed and water were available ad libitum over an experimental period of 42 days. Body weight
and feed intake were measured at days 1, 14 and 42, and feed to gain ratio calculated. An ANOVA
was performed with the data. Signiﬁcance level was set at p < 0.05.
The results of the two studies are presented in Table 3. No signiﬁcant differences between the
treatments were identiﬁed in any of the parameters evaluated.
3.3.2.3. Conclusions in weaned piglets
A higher metabolisable energy content of the diet was found in the piglets receiving the additive at
the recommended dose in one trial. No other signiﬁcant effects were found in the other three trials
considered in the evaluation. Therefore, the FEEDAP Panel cannot conclude on the efﬁcacy of
Bergazym® P100 in weaned piglets.
3.3.3. Pigs for fattening
Two short-term trials and one long-term trial conducted in the same trial site were evaluated.
3.3.3.1. Short-term trials
Two balance trials were considered which followed the same design and methodologies.34
Each balance study was performed with eight female pigs for fattening (Italian Duroc) housed in
individual digestibility cages and allocated to two dietary treatments (four pigs per treatment). The
mean body weight of the pigs involved in the two studies was 35.7 kg (study 1) and 83.8 kg (study
2), respectively. Each balance study was arranged in a 2 9 4 Latin square design: two phases
(rotation) of 7 days each with 4 days of total collection of faeces and urine (separated) and an
adaption period of 7 days. The basal diets based on wheat, sorghum and soya bean meal, were either
not supplemented (control) or supplemented with Bergazym® P100 to provide 1,500 EPU/kg feed. The
enzyme activity was conﬁrmed by analysis in the two studies. The diets were fed restrictively at 8% of
the pigs’ metabolic body weight (body weight0.75).
Body weight of the pigs was recorded at start, days 7, 14 and 21 and feed intake daily during
collection period in both phases. Faeces and urine were totally collected from days 4 to 7 in both
phases. Diets and faeces were analysed for dry matter, crude protein, crude fat and gross energy, and
the apparent faecal digestibilities were calculated. Urine was analysed for nitrogen content and
retention was calculated. The metabolisable energy content of the diets was calculated using the data
on the apparent faecal digestibility and the energy excreted through urine. An ANOVA was performed
with the data. Signiﬁcance level was set at p < 0.05.
The metabolisable energy content of the diets was 15.1 and 15.4 MJ/kg feed for the control and
the recommended dose group in study 1 and 14.1 and 14.6 MJ/kg feed in study 2. The values
obtained in the two studies for the pigs receiving the additive at the recommended dose were
signiﬁcantly higher compared to those found in the control diet.
Table 3: Effects of Bergazym P100 on the performance of weaned piglets
Trial Treatments
Feed intake
(g/day)
Body weight (kg) Feed to
gain ratio
Mortality and
culling (n)Initial Final
1 0 425 5.0 17.4 1.44 0
1,500 423 5.0 17.5 1.42 6
150,000 422 5.0 17.6 1.41 2
2 0 611 6.5 24.4 1.44 1
1,500 617 6.5 24.6 1.43 0
34 Technical dossier/Section IV/Annex 4.2.3.1.a-i. and Supplementary information November 2016/Annex 25.a-d.
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3.3.3.2. Long-term trial
A total of 144 female and castrated male pigs (Italian Duroc, approx. 63 days old and initial body
weight of 22.6 kg) were distributed to pens in groups of six pigs each (gender separated) and
allocated to two dietary treatments (representing 12 replicate pens per treatment).35 Basal diets
(grower and ﬁnisher) based on wheat, sorghum and soya bean meal were either not supplemented
(control) or supplemented with Bergazym® P100 to provide xylanase at 1,500 EPU/kg feed. The
enzyme activity was conﬁrmed by analysis. Health status and mortality were monitored daily. Feed and
water were available ad libitum over an experimental period of 112 days. Body weight and feed intake
were recorded at days 1, 56 and 112, and feed to gain ratio calculated. An ANOVA was performed
with the data considering the pen as the experimental unit. Signiﬁcance level was set at p < 0.05.
No pig died during the experiment. Mean daily feed intake was 2,030 and 2,010 g for control and
recommended dose, respectively. The corresponding values for ﬁnal body weight were 92.1 and
93.8 kg and for feed to gain ratio 3.27 and 3.18. Final body weight and feed to gain ratio were
signiﬁcantly higher in the pigs fed the recommended dose compared to control.
The FEEDAP Panel considers that in order to reﬂect different production conditions within the
European Union, the trials should be carried out in at least two different locations. It is noted that the
three studies in pigs for fattening were conducted in the same trial site. The Panel considers that the
production conditions would have little impact on the parameters measured in short-term trials, and
therefore this limitation is of little consequence for this assessment.
3.3.3.3. Conclusions for pigs for fattening
The additive has the potential to be efﬁcacious in pigs for fattening at the recommended dose.
3.4. Post-market monitoring
The FEEDAP Panel considers that there is no need for speciﬁc requirements for a post-market
monitoring plan other than those established in the Feed Hygiene Regulation36 and Good
Manufacturing Practice.
4. Conclusions
The additive is safe for chickens for fattening, weaned piglets and pigs for fattening at the
recommended dose (1,500 EPU/kg feed).
The use of Bergazym® P100 as a feed additive does not give rise to concerns for consumers of
animal products.
The additive is not irritant to skin or eyes but is considered a potential skin and respiratory
sensitiser.
The use of Bergazym® P100 poses no risks to the environment.
The Panel cannot conclude on the efﬁcacy of Bergazym® P100 for chickens for fattening and
weaned piglets. The Panel concludes that Bergazym® P100 has the potential to be efﬁcacious as a
zootechnical additive in pigs for fattening at the recommended dose.
Documentation provided to EFSA
1) Bergazym® P100. August 2014. Submitted by Berg + Schmidt GmbH Co. KG.
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Methods(s) of Analysis for Bergazym® P100.
4) Comments from Member States.
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Annex A – Executive Summary of the Evaluation Report of the European
Union Reference Laboratory for Feed Additives on the Methods of Analysis
for Bergazym® P100
In the current application authorisation is sought for Bergazym P100 under article 4(1) under the
category/functional 4(a) “zootechnical additives’/’digestibility enhancers” according to the classiﬁcation
system of Annex I of Regulation (EC) No 1831/2003. Speciﬁcally, authorisation is sought for the use of
the feed additive for chickens for fattening, weaned pigs and pigs for fattening.
According to the Applicant, endo-1,4-b-xylanase produced by Trichoderma reesei (MUCL 49755) is
the active substance of Bergazym P100. The Applicant expresses the xylanase enzymatic activity in
endopentosanase units (EPU), deﬁned as “the amount of enzyme which releases 0.0083 lmol of
reducing sugars (xylose equivalent) per minute from oat spelt xylan at pH 4.7 and 50°C”.
The feed additive is intended to be included through premixtures or directly in feedingstuffs to
obtain a minimum activity of 1,500 EPU/kg in feedingstuffs for all the target species.
For the quantiﬁcation of xylanase activity in the feed additive, premixtures and feedingstuffs the
Applicant submitted a single-laboratory validated and further veriﬁed method based on the
quantiﬁcation of water soluble dyed fragments produced by the action of xylanase on a commercially
available azurine cross-linked arabinoxylan substrate. External calibration is conducted using a
reference standard with a known enzyme activity expressed in EPU. Based on the satisfactory
performance characteristics the EURL recommends for ofﬁcial control the proposed single-laboratory
validated and further veriﬁed colorimetric method for the quantiﬁcation of the xylanase activity in the
feed additive, premixtures and feedingstuffs.
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